This week, Nature Medicine published results from an innovative trial in anhedonia. Anhedonia, or lack of pleasure, is a key symptom in a number of mood and anxiety disorders including depression. VeraSci experts Dr. Rich Keefe, CEO, and Trina Walker, VP Clinical Assessments, were collaborators on this study funded by the National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH). The trial demonstrated that the kappa opioid receptor (KOR) is a potential target for new treatments for anhedonia. The innovative fast-fail approach utilized by the trial allows researchers to assess whether targeting a particular biological mechanism will have the desired effect. Clinical trials in CNS disorders have a notoriously low success rate, and this fast-fail approach has the potential to improve efficiency and decrease the cost of developing new treatments for CNS disorders.